LB 100
Alternative Names: LB-1; LB-100Latest Information Update: 28 Apr 2024
At a glance
- Originator Lixte Biotechnology Holdings
- Developer City of Hope National Medical Center; Grupo Espanol de Investigacion en Sarcomas; INSERM; Lixte Biotechnology Holdings; M. D. Anderson Cancer Center; National Cancer Institute (USA)
- Class Anti-ischaemics; Antidepressants; Antineoplastics; Behavioural disorder therapies; Carboxylic acids; Heterocyclic bicyclo compounds; Piperazines; Small molecules
- Mechanism of Action Protein phosphatase 2A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- Phase II Glioblastoma
- Phase I/II Myelodysplastic syndromes; Ovarian cancer; Soft tissue sarcoma
- Preclinical Behavioural disorders
- No development reported Angelman syndrome; Ischaemia; Small cell lung cancer; Solid tumours
- Discontinued Depressive disorders; Haematological disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Combination therapy, Late-stage disease, Treatment-naive, In adults) in USA (IV)
- 27 Mar 2024 Pharmacodynamics and adverse events data from preclinical trial in Cancer released by Lixte Biotechnology
- 19 Mar 2024 Lixte Biotechnology Holdings receives patent allowance for LB 100 in the US